S. Caleb Freeman

S. Caleb Freeman

Auto-generated profile, based on publicly available information

S. Caleb Freeman

Department of Dermatology, Oregon Health & Science University, Portland, Oregon, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2022 in JID Innovations
Verified
Journal Article
Open access
EBElliot D. Blue
Elliot D. Blue
SFS. Caleb Freeman
S. Caleb Freeman
MLMarissa B. Lobl
Marissa B. Lobl
DCDillon D. Clarey
Dillon D. Clarey
RFRose L. Fredrick
Rose L. Fredrick
MWMelodi Javid Whitley
Melodi Javid Whitley
As solid organ transplantation becomes more prevalent, more individuals are living as members of the immunosuppressed population with an elevated risk for cutaneous squamous cell carcinoma (cSCC). Although great progress has been made in understanding the pathogenesis of cSCC in general, little is known about the drivers of tumorigenesis in immunosuppressed patients and organ-transplant recipients, specifically. This systematic review sought to synthesize information regarding the genetic and epigenetic alterations as well as changes in protein and mRNA expression that place this growing population at risk for cSCC, influence treatment response, and promote tumor aggressiveness. This review will provide investigators with a framework to identify future areas of investigation and clinicians with additional insight into how to best manage these patients.

3 February 2021 in Pediatric Dermatology
Verified
Journal Article
Closed access
PDF file
SFS. Caleb Freeman
S. Caleb Freeman
MDMary K. Dick
Mary K. Dick
RARoshan Abid
Roshan Abid
TTTaylor M. Tabatabai
Taylor M. Tabatabai
KBKristen G. Berrebi
Kristen G. Berrebi
JPJennifer G. Powers
Jennifer G. Powers

20 May 2020 in Cureus
Verified
Journal Article
Open access
PDF file
AGAlheli Arce Gastelum
Alheli Arce Gastelum
TVThomas Volberding
Thomas Volberding
SFS. Caleb Freeman
S. Caleb Freeman
MDMary Dick
Mary Dick
MGMaryam Gbadamosi-Akindele
Maryam Gbadamosi-Akindele
Historically, elevations in procalcitonin (PCT) have been implicated in medullary thyroid cancer and neuroendocrine tumors. More recently, the trending of PCT has been suggested as a monitor of infection to assess the presence, clearance and eradication of infection, especially in cancer patients. Its increase serves as a marker of bacterial infections. During homeostasis it is produced by most tissues in the body at an extremely low level (<.01 ng/mL) and is often induced by bacterial endotoxins. In cancer patients additional factors influence these levels. Metastasis in particular is linked with relatively higher PCT levels. We present a case of an afebrile patient with undifferentiated pleomorphic sarcoma who underwent 25 cycles of radiation therapy and presented one month later with elevated procalcitonin, lactic acid, and leukocytosis. All infectious work up was negative. Findings were incidental after a hospital visit for dehydration. Leukocytosis and lactic acidosis resolved after four days into the hospitalization. Procalcitonin, however, remained elevated over four months in the range of 2-5 ng/mL. The patient has no findings of metastatic disease. To our knowledge, there has never been a report in the literature describing a prolonged elevation of procalcitonin in a patient with a non-metastatic sarcoma without any signs of infection or any other underlying cause. The elevation of PCT has been noted in patients who suffered burns, trauma, minor and major surgery, and cardiogenic shock in addition to infection. Increases have served as signs of worsening patient outcomes and elevated rate of complications. Trending PCT can help in appropriated antibiotic use as it has been shown to decrease antibiotic use by 2.4 days. PCT trends have been increasing in value making idiopathic elevations found in combination undifferentiated pleomorphic sarcoma an important addition to the literature.